Targeting DCLK1 Attenuates Tumor Stemness and Evokes Antitumor Immunity in Triple-Negative Breast Cancer by Inhibiting IL-6/STAT3 Signaling

Investigators explored the impacts of doublecortin-like kinase 1 (DCLK1) on tumor cells as well as their immune microenvironment in triple-negative breast cancer (TNBC) and potential therapeutic strategies for TNBC patients with high DCLK1 expression.